Global Influenza Market: Size, Trends and Forecast (2018-2022)
Scope of the Report
The report entitled “Global Influenza Market: Size, Trends and Forecast (2018-2022)” provides an in-depth analysis of the influenza market including detailed description of market sizing and growth. The report provides analysis of the influenza market by value, by segments and includes segment analysis as well. The report also provides regional analysis of the influenza market for the US, Asia Pacific and rest of the world.
Moreover, the report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global influenza market has also been forecasted for the period 2018-2022, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.
The major players dominating the influenza market are GlaxoSmithKline (GSK), AstraZeneca, Thermo Fisher Scientific and Abbott Laboratories. The four companies have been profiled in the report providing detailed analysis of their financial information and business strategies.
Country Coverage
Influenza or flu is a respiratory illness which is caused by the influenza virus. The disease causes multiple complications for the people infected with the virus, particularly the elderly people and people suffering from chronic diseases as they are more susceptible to infections due to weak immune systems. Influenza might also prove to be fatal in some cases.
The best way to reduce the incidence and spread of influenza is to get vaccinated against the virus. Governments of various countries are actively involved in conducting several vaccination programs for the immunization of people against influenza. New and improved vaccines are being developed which provides a broader coverage against the virus. Various diagnostic tests and products are also available in the market for timely diagnosis of the flu so that proper treatment can be provided to the patients before their condition worsens.
The global influenza market has been segmented into vaccines, diagnostics and therapeutics. The influenza diagnostic market has been further segmented on the basis of test types into reverse transcription polymerase chain reaction (RT-PCR), rapid influenza diagnostic test (RIDT) and cell culture.
The global influenza market has witnessed continuous growth in the past few years and is projected to grow even further during the forecast period (2018-2022). The market is expected to be driven by various growth enhancing factors such as aging population, increasing awareness about influenza prevention, growing government initiatives to counter influenza, increasing healthcare expenditure and growing prevalence of chronic diseases. However, the market is not free from challenges that are hindering its growth. Some of the major challenges faced by the market are the high cost of vaccine development and the low influenza vaccination awareness in developing countries.
The report entitled “Global Influenza Market: Size, Trends and Forecast (2018-2022)” provides an in-depth analysis of the influenza market including detailed description of market sizing and growth. The report provides analysis of the influenza market by value, by segments and includes segment analysis as well. The report also provides regional analysis of the influenza market for the US, Asia Pacific and rest of the world.
Moreover, the report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global influenza market has also been forecasted for the period 2018-2022, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.
The major players dominating the influenza market are GlaxoSmithKline (GSK), AstraZeneca, Thermo Fisher Scientific and Abbott Laboratories. The four companies have been profiled in the report providing detailed analysis of their financial information and business strategies.
Country Coverage
- Asia Pacific
- The US
- ROW (Rest of the World)
- GlaxoSmithKline (GSK)
- AstraZeneca
- Thermo Fisher Scientific
- Abbott Laboratories
Influenza or flu is a respiratory illness which is caused by the influenza virus. The disease causes multiple complications for the people infected with the virus, particularly the elderly people and people suffering from chronic diseases as they are more susceptible to infections due to weak immune systems. Influenza might also prove to be fatal in some cases.
The best way to reduce the incidence and spread of influenza is to get vaccinated against the virus. Governments of various countries are actively involved in conducting several vaccination programs for the immunization of people against influenza. New and improved vaccines are being developed which provides a broader coverage against the virus. Various diagnostic tests and products are also available in the market for timely diagnosis of the flu so that proper treatment can be provided to the patients before their condition worsens.
The global influenza market has been segmented into vaccines, diagnostics and therapeutics. The influenza diagnostic market has been further segmented on the basis of test types into reverse transcription polymerase chain reaction (RT-PCR), rapid influenza diagnostic test (RIDT) and cell culture.
The global influenza market has witnessed continuous growth in the past few years and is projected to grow even further during the forecast period (2018-2022). The market is expected to be driven by various growth enhancing factors such as aging population, increasing awareness about influenza prevention, growing government initiatives to counter influenza, increasing healthcare expenditure and growing prevalence of chronic diseases. However, the market is not free from challenges that are hindering its growth. Some of the major challenges faced by the market are the high cost of vaccine development and the low influenza vaccination awareness in developing countries.
1. EXECUTIVE SUMMARY
2. INTRODUCTION
2.1 Influenza: An Overview
2.1.1 Symptoms of Influenza
2.1.2 History of Influenza
2.1.3 Influenza Drift and Shift Process
2.1.4 Influenza Types
2.1.5 Influenza Prevention
2.2 Advantages of Influenza Vaccines
2.3 Influenza Segmentation: An Overview
3. GLOBAL MARKET ANALYSIS
3.1 Global Influenza Market: An Analysis
3.1.1 Global Influenza Market by Value
3.1.2 Global Influenza Market by Segments (Vaccines, Therapeutics, Diagnostics)
3.2 Global Influenza Market: Segment Analysis
3.2.1 Global Influenza Vaccines Market by Value
3.2.2 Global Influenza Vaccines Market by Region (The US, Asia Pacific, ROW)
3.2.3 Global Influenza Therapeutics Market by Value
3.2.4 Global Influenza Diagnostics Market by Value
3.2.5 Global Influenza Diagnostics Market by Test Type (Rapid Influenza Diagnostic Test (RIDT), Reverse Transcription Polymerase Chain Reaction (RT-PCR), Cell Culture)
3.2.6 Global RIDT Market by Value
3.2.7 Global RT-PCR Influenza Diagnostic Test Market by Value
3.2.8 Global Cell Culture Influenza Diagnostic Test Market by Value
4. REGIONAL MARKET ANALYSIS
4.1 Asia Pacific Influenza Vaccine Market: An Analysis
4.1.1 Asia Pacific Influenza Vaccine Market by Value
4.1.2 Asia Pacific Influenza Vaccine Market by Vaccine Type (Quadrivalent, Trivalent)
4.1.3 Asia Pacific Quadrivalent Influenza Vaccine Market by Value
4.1.4 Asia Pacific Trivalent Influenza Vaccine Market by Value
4.2 The US Influenza Vaccine Market: An Analysis
4.2.1 The US Influenza Vaccine Market by Value
4.2.2 The US Influenza Vaccine Market by Vaccine Type (Quadrivalent, Trivalent)
4.2.3 The US Quadrivalent Influenza Vaccine Market by Value
4.2.4 The US Trivalent Influenza Vaccine Market by Value
4.3 The US Influenza Diagnostic Market: An Analysis
4.3.1 The US Influenza Diagnostic Market by Value
4.3.2 The US Influenza Diagnostic Market by Test Type (Rapid Influenza Diagnostic Test (RIDT), Reverse Transcription Polymerase Chain Reaction (RT-PCR), Cell Culture, Others)
4.3.3 The US RIDT Market by Value
4.3.4 The US RT-PCR Influenza Diagnostic Test Market by Value
4.3.5 The US Cell Culture Influenza Diagnostic Test Market by Value
4.3.6 The US Other Influenza Diagnostic Test Market by Value
4.3.7 The US Influenza Diagnostic Market by End-use (Hospitals, Point-of-Care Testing (POCT), Laboratories)
4.3.8 The US Hospitals Influenza Diagnostic Market by Value
4.3.9 The US Point-of-Care Testing (POCT) Influenza Diagnostic Market by Value
4.3.10 The US Laboratories Influenza Diagnostic Market by Value
4.4 ROW Influenza Vaccines Market: An Analysis
4.4.1 ROW Influenza Vaccines Market by Value
5. MARKET DYNAMICS
5.1 Growth Drivers
5.1.1 Aging Population
5.1.2 Increasing Healthcare Expenditure
5.1.3 Growing Prevalence of Chronic Diseases
5.1.4 Increasing Awareness about Influenza Prevention
5.1.5 Growing Government Initiatives to Counter Influenza
5.2 Challenges
5.2.1 High Cost of Vaccine Development
5.2.2 Low Influenza Vaccination Awareness in Developing Countries
5.3 Market Trends
5.3.1 Increasing Vaccination Coverage
5.3.2 Use of Intranasal Influenza Vaccines
5.3.3 Cell Culture Technology
5.3.4 Development of Point-of-Care Molecular Tests
6. COMPETITIVE LANDSCAPE
6.1 Global Influenza Market Players: Financial Comparison
6.2 Global Influenza Market Players by Influenza Vaccine Clinical Trials
6.3 Global Influenza Market Players by Influenza Vaccines Produced
7. COMPANY PROFILES
7.1 GlaxoSmithKline (GSK)
7.1.1 Business Overview
7.1.2 Financial Overview
7.1.3 Business Strategy
7.2 AstraZeneca
7.2.1 Business Overview
7.2.2 Financial Overview
7.2.3 Business Strategy
7.3 Thermo Fisher Scientific
7.3.1 Business Overview
7.3.2 Financial Overview
7.3.3 Business Strategy
7.4 Abbott Laboratories
7.4.1 Business Overview
7.4.2 Financial Overview
7.4.3 Business Strategy
2. INTRODUCTION
2.1 Influenza: An Overview
2.1.1 Symptoms of Influenza
2.1.2 History of Influenza
2.1.3 Influenza Drift and Shift Process
2.1.4 Influenza Types
2.1.5 Influenza Prevention
2.2 Advantages of Influenza Vaccines
2.3 Influenza Segmentation: An Overview
3. GLOBAL MARKET ANALYSIS
3.1 Global Influenza Market: An Analysis
3.1.1 Global Influenza Market by Value
3.1.2 Global Influenza Market by Segments (Vaccines, Therapeutics, Diagnostics)
3.2 Global Influenza Market: Segment Analysis
3.2.1 Global Influenza Vaccines Market by Value
3.2.2 Global Influenza Vaccines Market by Region (The US, Asia Pacific, ROW)
3.2.3 Global Influenza Therapeutics Market by Value
3.2.4 Global Influenza Diagnostics Market by Value
3.2.5 Global Influenza Diagnostics Market by Test Type (Rapid Influenza Diagnostic Test (RIDT), Reverse Transcription Polymerase Chain Reaction (RT-PCR), Cell Culture)
3.2.6 Global RIDT Market by Value
3.2.7 Global RT-PCR Influenza Diagnostic Test Market by Value
3.2.8 Global Cell Culture Influenza Diagnostic Test Market by Value
4. REGIONAL MARKET ANALYSIS
4.1 Asia Pacific Influenza Vaccine Market: An Analysis
4.1.1 Asia Pacific Influenza Vaccine Market by Value
4.1.2 Asia Pacific Influenza Vaccine Market by Vaccine Type (Quadrivalent, Trivalent)
4.1.3 Asia Pacific Quadrivalent Influenza Vaccine Market by Value
4.1.4 Asia Pacific Trivalent Influenza Vaccine Market by Value
4.2 The US Influenza Vaccine Market: An Analysis
4.2.1 The US Influenza Vaccine Market by Value
4.2.2 The US Influenza Vaccine Market by Vaccine Type (Quadrivalent, Trivalent)
4.2.3 The US Quadrivalent Influenza Vaccine Market by Value
4.2.4 The US Trivalent Influenza Vaccine Market by Value
4.3 The US Influenza Diagnostic Market: An Analysis
4.3.1 The US Influenza Diagnostic Market by Value
4.3.2 The US Influenza Diagnostic Market by Test Type (Rapid Influenza Diagnostic Test (RIDT), Reverse Transcription Polymerase Chain Reaction (RT-PCR), Cell Culture, Others)
4.3.3 The US RIDT Market by Value
4.3.4 The US RT-PCR Influenza Diagnostic Test Market by Value
4.3.5 The US Cell Culture Influenza Diagnostic Test Market by Value
4.3.6 The US Other Influenza Diagnostic Test Market by Value
4.3.7 The US Influenza Diagnostic Market by End-use (Hospitals, Point-of-Care Testing (POCT), Laboratories)
4.3.8 The US Hospitals Influenza Diagnostic Market by Value
4.3.9 The US Point-of-Care Testing (POCT) Influenza Diagnostic Market by Value
4.3.10 The US Laboratories Influenza Diagnostic Market by Value
4.4 ROW Influenza Vaccines Market: An Analysis
4.4.1 ROW Influenza Vaccines Market by Value
5. MARKET DYNAMICS
5.1 Growth Drivers
5.1.1 Aging Population
5.1.2 Increasing Healthcare Expenditure
5.1.3 Growing Prevalence of Chronic Diseases
5.1.4 Increasing Awareness about Influenza Prevention
5.1.5 Growing Government Initiatives to Counter Influenza
5.2 Challenges
5.2.1 High Cost of Vaccine Development
5.2.2 Low Influenza Vaccination Awareness in Developing Countries
5.3 Market Trends
5.3.1 Increasing Vaccination Coverage
5.3.2 Use of Intranasal Influenza Vaccines
5.3.3 Cell Culture Technology
5.3.4 Development of Point-of-Care Molecular Tests
6. COMPETITIVE LANDSCAPE
6.1 Global Influenza Market Players: Financial Comparison
6.2 Global Influenza Market Players by Influenza Vaccine Clinical Trials
6.3 Global Influenza Market Players by Influenza Vaccines Produced
7. COMPANY PROFILES
7.1 GlaxoSmithKline (GSK)
7.1.1 Business Overview
7.1.2 Financial Overview
7.1.3 Business Strategy
7.2 AstraZeneca
7.2.1 Business Overview
7.2.2 Financial Overview
7.2.3 Business Strategy
7.3 Thermo Fisher Scientific
7.3.1 Business Overview
7.3.2 Financial Overview
7.3.3 Business Strategy
7.4 Abbott Laboratories
7.4.1 Business Overview
7.4.2 Financial Overview
7.4.3 Business Strategy
LIST OF FIGURES
Figure 1: Symptoms of Influenza
Figure 2: Pandemic Influenza History
Figure 3: Influenza Drift and Shift Process
Figure 4: Influenza Types
Figure 5: Advantages of Influenza Vaccines
Figure 6: Influenza Segmentation
Figure 7: Global Influenza Market by Value; 2016-2017 (US$ Billion)
Figure 8: Global Influenza Market by Value; 2018-2022 (US$ Billion)
Figure 9: Global Influenza Market by Segments; 2017 (Percentage, %)
Figure 10: Global Influenza Vaccines Market by Value; 2016-2017 (US$ Billion)
Figure 11: Global Influenza Vaccines Market by Value; 2018-2022 (US$ Billion)
Figure 12: Global Influenza Vaccines Market by Region; 2017 (Percentage, %)
Figure 13: Global Influenza Therapeutics Market by Value; 2016-2017 (US$ Billion)
Figure 14: Global Influenza Therapeutics Market by Value; 2018-2022 (US$ Billion)
Figure 15: Global Influenza Diagnostics Market by Value; 2016-2017 (US$ Billion)
Figure 16: Global Influenza Diagnostics Market by Value; 2018-2022 (US$ Billion)
Figure 17: Global Influenza Diagnostics Market by Test Type; 2017 (Percentage, %)
Figure 18: Global RIDT Market by Value; 2016-2017 (US$ Million)
Figure 19: Global RIDT Market by Value; 2018-2022 (US$ Million)
Figure 20: Global RT-PCR Influenza Diagnostic Test Market by Value; 2016-2017 (US$ Million)
Figure 21: Global RT-PCR Influenza Diagnostic Test Market by Value; 2018-2022 (US$ Million)
Figure 22: Global Cell Culture Influenza Diagnostic Test Market by Value; 2016-2017 (US$ Million)
Figure 23: Global Cell Culture Influenza Diagnostic Test Market by Value; 2018-2022 (US$ Million)
Figure 24: Asia Pacific Influenza Vaccine Market by Value; 2016-2017 (US$ Billion)
Figure 25: Asia Pacific Influenza Vaccine Market by Value; 2018-2022 (US$ Billion)
Figure 26: Asia Pacific Influenza Vaccine Market by Vaccine Type; 2017 (Percentage, %)
Figure 27: Asia Pacific Quadrivalent Influenza Vaccine Market by Value; 2016-2017 (US$ Million)
Figure 28: Asia Pacific Quadrivalent Influenza Vaccine Market by Value; 2018-2022 (US$ Million)
Figure 29: Asia Pacific Trivalent Influenza Vaccine Market by Value; 2016-2017 (US$ Million)
Figure 30: Asia Pacific Trivalent Influenza Vaccine Market by Value; 2018-2022 (US$ Million)
Figure 31: The US Influenza Vaccine Market by Value; 2016-2017 (US$ Billion)
Figure 32: The US Influenza Vaccine Market by Value; 2018-2022 (US$ Billion)
Figure 33: The US Influenza Vaccine Market by Vaccine Type; 2017 (Percentage, %)
Figure 34: The US Quadrivalent Influenza Vaccine Market by Value; 2016-2017 (US$ Billion)
Figure 35: The US Quadrivalent Influenza Vaccine Market by Value; 2018-2022 (US$ Billion)
Figure 36: The US Trivalent Influenza Vaccine Market by Value; 2016-2017 (US$ Billion)
Figure 37: The US Trivalent Influenza Vaccine Market by Value; 2018-2022 (US$ Billion)
Figure 38: The US Influenza Diagnostic Market by Value; 2016-2017 (US$ Million)
Figure 39: The US Influenza Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 40: The US Influenza Diagnostic Market by Test Type; 2017 (Percentage, %)
Figure 41: The US RIDT Market by Value; 2016-2017 (US$ Million)
Figure 42: The US RIDT Market by Value; 2018-2022 (US$ Million)
Figure 43: The US RT-PCR Influenza Diagnostic Test Market by Value; 2016-2017 (US$ Million)
Figure 44: The US RT-PCR Influenza Diagnostic Test Market by Value; 2018-2022 (US$ Million)
Figure 45: The US Cell Culture Influenza Diagnostic Test Market by Value; 2016-2017 (US$ Million)
Figure 46: The US Cell Culture Influenza Diagnostic Test Market by Value; 2018-2022 (US$ Million)
Figure 47: The US Other Influenza Diagnostic Test Market by Value; 2016-2017 (US$ Million)
Figure 48: The US Other Influenza Diagnostic Test Market by Value; 2018-2022 (US$ Million)
Figure 49: The US Influenza Diagnostic Market by End-use; 2017 (Percentage, %)
Figure 50: The US Hospitals Influenza Diagnostic Market by Value; 2016-2017 (US$ Million)
Figure 51: The US Hospitals Influenza Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 52: The US Point-of-Care Testing Influenza Diagnostic Market by Value; 2016-2017 (US$ Million)
Figure 53: The US Point-of-Care Testing Influenza Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 54: The US Laboratories Influenza Diagnostic Market by Value; 2016-2017 (US$ Million)
Figure 55: The US Laboratories Influenza Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 56: ROW Influenza Vaccines Market by Value; 2016-2017 (US$ Billion)
Figure 57: ROW Influenza Vaccines Market by Value; 2018-2022 (US$ Billion)
Figure 58: Global Population by Age Groups; 2015-2030 (Million)
Figure 59: Global Healthcare Expenditure, 1995-2022 (US$ Trillion)
Figure 60: Growth in Chronic Diseases in the US; 2016-2025 (Percentage, %)
Figure 61: The US Seasonal Flu Vaccination Coverage; 2013-2017 (Percentage, %)
Figure 62: GlaxoSmithKline Turnover; 2013-2017 (US$ Billion)
Figure 63: GlaxoSmithKline Turnover by Segments; 2017 (Percentage, %)
Figure 64: GlaxoSmithKline Turnover by Region; 2017 (Percentage, %)
Figure 65: AstraZeneca Total Revenue; 2013-2017 (US$ Billion)
Figure 66: AstraZeneca Total Revenue by Region; 2017 (Percentage, %)
Figure 67: Thermo Fisher Scientific Revenue; 2013-2017 (US$ Billion)
Figure 68: Thermo Fisher Scientific Revenue by Segments; 2017 (Percentage, %)
Figure 69: Thermo Fisher Scientific Revenue by Region; 2017 (Percentage, %)
Figure 70: Abbott Laboratories Net Sales; 2013-2017 (US$ Billion)
Figure 71: Abbott Laboratories Net Sales by Segments; 2017 (Percentage, %)
Figure 72: Abbott Laboratories Net Sales by Region; 2017 (Percentage, %)
Figure 1: Symptoms of Influenza
Figure 2: Pandemic Influenza History
Figure 3: Influenza Drift and Shift Process
Figure 4: Influenza Types
Figure 5: Advantages of Influenza Vaccines
Figure 6: Influenza Segmentation
Figure 7: Global Influenza Market by Value; 2016-2017 (US$ Billion)
Figure 8: Global Influenza Market by Value; 2018-2022 (US$ Billion)
Figure 9: Global Influenza Market by Segments; 2017 (Percentage, %)
Figure 10: Global Influenza Vaccines Market by Value; 2016-2017 (US$ Billion)
Figure 11: Global Influenza Vaccines Market by Value; 2018-2022 (US$ Billion)
Figure 12: Global Influenza Vaccines Market by Region; 2017 (Percentage, %)
Figure 13: Global Influenza Therapeutics Market by Value; 2016-2017 (US$ Billion)
Figure 14: Global Influenza Therapeutics Market by Value; 2018-2022 (US$ Billion)
Figure 15: Global Influenza Diagnostics Market by Value; 2016-2017 (US$ Billion)
Figure 16: Global Influenza Diagnostics Market by Value; 2018-2022 (US$ Billion)
Figure 17: Global Influenza Diagnostics Market by Test Type; 2017 (Percentage, %)
Figure 18: Global RIDT Market by Value; 2016-2017 (US$ Million)
Figure 19: Global RIDT Market by Value; 2018-2022 (US$ Million)
Figure 20: Global RT-PCR Influenza Diagnostic Test Market by Value; 2016-2017 (US$ Million)
Figure 21: Global RT-PCR Influenza Diagnostic Test Market by Value; 2018-2022 (US$ Million)
Figure 22: Global Cell Culture Influenza Diagnostic Test Market by Value; 2016-2017 (US$ Million)
Figure 23: Global Cell Culture Influenza Diagnostic Test Market by Value; 2018-2022 (US$ Million)
Figure 24: Asia Pacific Influenza Vaccine Market by Value; 2016-2017 (US$ Billion)
Figure 25: Asia Pacific Influenza Vaccine Market by Value; 2018-2022 (US$ Billion)
Figure 26: Asia Pacific Influenza Vaccine Market by Vaccine Type; 2017 (Percentage, %)
Figure 27: Asia Pacific Quadrivalent Influenza Vaccine Market by Value; 2016-2017 (US$ Million)
Figure 28: Asia Pacific Quadrivalent Influenza Vaccine Market by Value; 2018-2022 (US$ Million)
Figure 29: Asia Pacific Trivalent Influenza Vaccine Market by Value; 2016-2017 (US$ Million)
Figure 30: Asia Pacific Trivalent Influenza Vaccine Market by Value; 2018-2022 (US$ Million)
Figure 31: The US Influenza Vaccine Market by Value; 2016-2017 (US$ Billion)
Figure 32: The US Influenza Vaccine Market by Value; 2018-2022 (US$ Billion)
Figure 33: The US Influenza Vaccine Market by Vaccine Type; 2017 (Percentage, %)
Figure 34: The US Quadrivalent Influenza Vaccine Market by Value; 2016-2017 (US$ Billion)
Figure 35: The US Quadrivalent Influenza Vaccine Market by Value; 2018-2022 (US$ Billion)
Figure 36: The US Trivalent Influenza Vaccine Market by Value; 2016-2017 (US$ Billion)
Figure 37: The US Trivalent Influenza Vaccine Market by Value; 2018-2022 (US$ Billion)
Figure 38: The US Influenza Diagnostic Market by Value; 2016-2017 (US$ Million)
Figure 39: The US Influenza Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 40: The US Influenza Diagnostic Market by Test Type; 2017 (Percentage, %)
Figure 41: The US RIDT Market by Value; 2016-2017 (US$ Million)
Figure 42: The US RIDT Market by Value; 2018-2022 (US$ Million)
Figure 43: The US RT-PCR Influenza Diagnostic Test Market by Value; 2016-2017 (US$ Million)
Figure 44: The US RT-PCR Influenza Diagnostic Test Market by Value; 2018-2022 (US$ Million)
Figure 45: The US Cell Culture Influenza Diagnostic Test Market by Value; 2016-2017 (US$ Million)
Figure 46: The US Cell Culture Influenza Diagnostic Test Market by Value; 2018-2022 (US$ Million)
Figure 47: The US Other Influenza Diagnostic Test Market by Value; 2016-2017 (US$ Million)
Figure 48: The US Other Influenza Diagnostic Test Market by Value; 2018-2022 (US$ Million)
Figure 49: The US Influenza Diagnostic Market by End-use; 2017 (Percentage, %)
Figure 50: The US Hospitals Influenza Diagnostic Market by Value; 2016-2017 (US$ Million)
Figure 51: The US Hospitals Influenza Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 52: The US Point-of-Care Testing Influenza Diagnostic Market by Value; 2016-2017 (US$ Million)
Figure 53: The US Point-of-Care Testing Influenza Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 54: The US Laboratories Influenza Diagnostic Market by Value; 2016-2017 (US$ Million)
Figure 55: The US Laboratories Influenza Diagnostic Market by Value; 2018-2022 (US$ Million)
Figure 56: ROW Influenza Vaccines Market by Value; 2016-2017 (US$ Billion)
Figure 57: ROW Influenza Vaccines Market by Value; 2018-2022 (US$ Billion)
Figure 58: Global Population by Age Groups; 2015-2030 (Million)
Figure 59: Global Healthcare Expenditure, 1995-2022 (US$ Trillion)
Figure 60: Growth in Chronic Diseases in the US; 2016-2025 (Percentage, %)
Figure 61: The US Seasonal Flu Vaccination Coverage; 2013-2017 (Percentage, %)
Figure 62: GlaxoSmithKline Turnover; 2013-2017 (US$ Billion)
Figure 63: GlaxoSmithKline Turnover by Segments; 2017 (Percentage, %)
Figure 64: GlaxoSmithKline Turnover by Region; 2017 (Percentage, %)
Figure 65: AstraZeneca Total Revenue; 2013-2017 (US$ Billion)
Figure 66: AstraZeneca Total Revenue by Region; 2017 (Percentage, %)
Figure 67: Thermo Fisher Scientific Revenue; 2013-2017 (US$ Billion)
Figure 68: Thermo Fisher Scientific Revenue by Segments; 2017 (Percentage, %)
Figure 69: Thermo Fisher Scientific Revenue by Region; 2017 (Percentage, %)
Figure 70: Abbott Laboratories Net Sales; 2013-2017 (US$ Billion)
Figure 71: Abbott Laboratories Net Sales by Segments; 2017 (Percentage, %)
Figure 72: Abbott Laboratories Net Sales by Region; 2017 (Percentage, %)
LIST OF TABLES
Table 1: Global Influenza Market Players Financial Comparison; 2017
Table 2: Global Influenza Market Players by Influenza Vaccine Clinical Trials; 2017
Table 3: Global Influenza Market Players by Influenza Vaccines Produced; 2017
Table 1: Global Influenza Market Players Financial Comparison; 2017
Table 2: Global Influenza Market Players by Influenza Vaccine Clinical Trials; 2017
Table 3: Global Influenza Market Players by Influenza Vaccines Produced; 2017
